Iptacopan in IgA Nephropathy — Final 24-Month Data
Jonathan Barratt·Vlado Perkovic·Thomas Hach·Annabel R. Magirr·Ronny Renfurm·Emil Scosyrev·Guangqun Xing·Seung Hyeok Han·ChuanMing Hao·Julia Weinmann-Menke·Wanhong Lu·Naoki Kashihara·Dana V. Rizk·Valter Duro Garcia·Ismail Kocyigit·Luca Monaco·Necmi Eren·Vladimir Tesař·Frank Eitner·Hong Zhang·Li Yang·Kenan Turgutalp·Antonio Pisani·Brad Rovin·Hernán Trimarchi·Bart Maes·Dmytro Butylin·Weiming Wang·Nicolas Guérard
Iptacopan therapy led to a significantly slower decline in kidney function than placebo. (Funded by Novartis; APPLAUSE-IgAN ClinicalTrials.gov number, NCT04578834.).